Tryptamine Therapeutics Limited
TYPTF
$0.015
$0.000.00%
| 12/31/2024 | 09/30/2024 | 02/29/2024 | 11/30/2023 | 08/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.31M | -1.35M | -914.30K | -850.10K | -1.27M |
| Total Depreciation and Amortization | 6.60K | 6.80K | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -333.60K | -343.00K | -341.00K | 152.50K | 303.40K |
| Change in Net Operating Assets | -- | -- | 12.50K | -12.20K | 125.40K |
| Cash from Operations | -1.64M | -1.69M | -1.24M | -709.70K | -839.50K |
| Capital Expenditure | -39.30K | -40.40K | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Investing | -39.30K | -40.40K | -- | -- | 0.00 |
| Total Debt Issued | -- | -- | 22.10K | 2.67M | 183.10K |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.38M | 1.38M | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -98.70K | -98.70K | -- | -- | -- |
| Cash from Financing | 831.70K | 855.20K | 14.70K | 1.95M | 137.40K |
| Foreign Exchange rate Adjustments | 32.00K | 32.90K | -1.70K | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -814.50K | -837.50K | -1.23M | 1.24M | -702.10K |
